This bill aims to strengthen the American pharmaceutical supply chain by reducing dependence on foreign drug manufacturing. The legislation requires the Department of Health and Human Services to develop and maintain a classified list of drugs critical to public health and national security within one year, updating it every two years. The bill authorizes $5 billion through 2029 for contracts with U.S. companies and nonprofits to manufacture these critical drugs and their ingredients domestically using advanced manufacturing techniques. Companies receiving contracts must maintain backup suppliers, keep three-month emergency supplies on hand, develop continuity plans, and charge fair and reasonable prices determined by the government. Beginning in fiscal year 2029, federal agencies like the Defense Department, Veterans Affairs, and the Bureau of Prisons must prioritize purchasing domestically manufactured drugs from the list, with $4 billion authorized through 2033 for these purchases. The bill also establishes new transparency requirements for domestic and foreign drug manufacturers, creates a registry of active pharmaceutical ingredients, and requires annual reports to Congress on foreign pharmaceutical investment in the United States.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.